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INTRODUCTION
Apolipoprotein E (apo E)' is the most actively synthetized apolipoprotein in the rat and appears to be of Dr. Retegui is Fellow of the Consejo Nacional de Investigaciones Cientificas y T6cnicas de la Republica Argentina.
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exclusively hepatic origin (1) (2) (3) . In humans as in swine, apo B and apo E are respectively responsible for the binding of low density lipoprotein (LDL) and of a minor high density lipoprotein (HDL) subclass to a high-affinity cell-surface receptor on fibroblasts and other cell types (4, 5) . The apo E and apo B are recognized by the same receptor and, in both cases, binding is abolished if the lysine or arginine residues of the apoproteins are chemically modified (6) . It has been suggested that structurally similar positively charged regions on the two apoproteins serve as the recognition site for the receptor (7) . In addition, apo E appears to be responsible for the hepatic uptake of a subfraction of homologous (8) and heterologous (9) HDL from rat plasma.
Monoclonal antibodies to apoproteins provide a new approach to the study of the specificity of the interaction of lipoproteins and cell surface receptors. The advantage of monoclonal antibodies lies in their specificity for a single antigenic determinant. It is possible that with a battery of monoclonal antibodies to an apoprotein one could immunochemically define regions of the apoprotein involved in binding to the cell surface receptor.
We report the production and partial characterization of five monoclonal antibodies against human apo E.
METHODS
Preparation of plasma and plasma lipoproteins. Blood from fasted normal subjects or from fasted type IIA, type III, or type IV hyperlipidemic patients of the lipid clinic of the Clinical Research Institute of Montreal was collected into EDTA.
Lipoprotein subfractions were prepared in a Beckman L5-65 ultracentrifuge with a 50.2 Ti rotor (Beckman Instruments, Inc., Spinco Div., Palo Alto, Calif.). The very low density lipoprotein (VLDL), LDL, and HDL were isolated at densities of 1.006, 1.006-1.063, and 1.063-1.21 g/ml, respectively. The infranate, d > 1.21 g/ml, was also retained for analysis.
Purification of apo E. The VLDL from normal fasted subjects was isolated as described above and delipidated with ethanol/diethylether (3:2) at a ratio of 25 vol of solvent/vol of VLDL. The VLDL precipitate was then subjected to two further extractions in diethylether. The moist apolipoprotein was redissolved in a buffer consisting of 2 mM phosphate, 5 M urea, and 10 mM dithiothreitol (pH 7.4). The sample was applied to a column of heparin (Upjohn Co., Kalamazoo, Mich.) bound to Sepharose 4B (10), which had been preequilibrated with 2 mM NaHPO4 and 5 M urea (pH 7.4). After extensive washing with the same buffer, the bound protein was eluted with 2 mM Na phosphate buffer (pH 7.4), 5 M urea, and 1 M NaCl. The retained fraction was dialyzed against 2 mM Na phosphate buffer (pH 7.4), made up to 5 M urea, and reapplied to the heparin-Sepharose column, which was conditioned as above. The bound protein was eluted with a linear gradient 50-300 mM NaCl in 2 mM Na phosphate buffer (pH 7.4) and 5 M urea. Apo E was eluted between 200 and 230 mM NaCl and its puirity checked by alkaline polyacrylamide gel electrophoresis, by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and by isoelectric focusing on polyacrylamide gel (11) . The isolated apo E did not cross-react with antisera against other apoproteins.
The major polymorphic species of apo E were isolated by preparative isoelectrofocusing (pI) of apo VLDL, as described previously (11 Immunization ofmice. BALB/c mice, whose spleens were to be used for cell fusion were given a primary subcutaneous injection of 50 ,ug of apo E in complete Freund's adjuvant. After 3 wk, the mice were given a second subcutaneous injection of 50 ,ug apo E in complete Freund's adjuvant. BALB/c mice were also immunized intraperitonally, according to the protocol of Tung et al. (13) , to induce ascites containing anti-apo E antibody.
Cellfusion. The technique used for cell fusion was similar to that described by Kennet et al. (14) . A cell suspension in Hanks' balanced salt solution (HBSS) was prepared by teasing apart the spleens of two appropriately immunized mice. The cells were filtered through nylon cloth and centrifuged, and the erythrocytes lysed by osmotic shock. The cells were again centrifuged, filtered through nylon cloth, and washed in HBSS. The SP2-0 cells were washed twice in HBSS, mixed with the spleen cells at a ratio of 1:10, and again washed in HBSS. The pellet was resuspended in 0.2 ml of30% polyethylene glycol 1000 (J. T. Baker Chemical Co., Phillipsburg, N. J.), gently swirled for 2 min, and centrifuged for 6 min at 200 g. 5 ml of HBSS was added and the cells gently swirled for 3 min followed by centrifugation. 5 ml of Dulbecco's modified Eagle's medium containing 15 mM Hepes, 40,M 2-mercaptoethanol, 30% FBS and penicillinstreptomycin was added. The pellet was left undisturbed for 5 min before gentle resuspension of the cells. The cells were diluted to 20 ml with medium and distributed in two petri plates. After 24 h the cells were centrifuged and resuspended in the same medium, which in addition contained 0.11 mM hypoxanthine, 0.38 ,uM aminopterine, and 16 ,uM thymidine (HAT) (15) . The cells were then distributed in the wells of 11, 96-well microculture plates (Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, Calif.). On 3 successive d, 50 ,ul of HAT-containing medium was added to each well. When sufficient growth had occurred, normally at 10-15 d, the supemate were screened for the presence of anti-apo E antibody.
Screening ofsupernates. Aliquots of200 ,u of a solution of apo E (10,ug/ml in 5 mM glycine, pH 9.2) were distributed in Removawells (Dynatech Laboratories, Inc., Dynatech Corp., Alexandria, Va.) and left overnight. The following day the wells were washed in 0.15 M NaCl containing 0.25% Tween 20. An aliquot of hybridoma supernate diluted to 200 ,ul in phosphate-buffered saline containing 5% FBS was added to each well and incubated for 3 h at 370C. The wells were washed in 0.15 M NaCl/0.025% Tween and 200 ,pl of purified 125I-anti-mouse Fab, diluted in phosphate-buffered saline containing 5% FBS was added and incubated for a further 3 h. The wells were washed and the bound radioactivity determined. To identify the immunoglobulin class and subclass of the antibody produced by positive clones, a similar radioimmunoassay was performed but with purified 1251-labeled antibody specific to an individual mouse immunoglobulin class or subclass substituted for the 125I-anti-Fab. The preparation of the anti-mouse immunoglobulin reagents has been described previously (16) .
Maintenance of hybridomas in culture and as ascitic tumors. Once positive clones were identified, the cells were transferred to larger culture vessels and maintained in HATcontaining medium. The concentration of FBS was gradually reduced from 30 to 10%.
Lightly irradiated (200-500 R) BALB/c mice were injected intraperitoneally with 5 x 106 cultured hybridoma cells. When sufficient ascitic fluid had accumulated, the mice were killed and the ascites collected. The ascitic cells were used to passage the tumor and the fluid was used as a source of monoclonal anti-apo E antibody.
Isolation of anti-apo E immunoglobulin. The IgG subclass containing the anti-apo E antibody was isolated from the ascitic fluid of hybridoma-bearing mice by elution from protein-A Sepharose 4B (Pharmacia Inc., Uppsala, Sweden) with a stepwise pH gradient (17) .
Iodination. 5 ,ug apo E was labeled with 1 mCi of 125I by the technique of Bolton and Hunter (18) . The prelabeled Bolton-Hunter reagent was purchased from Amersham Corp. (Arlington Heights, Ill.). The iodinated protein was isolated by gel filtration on Sephadex G-25. Greater than 90% of the radioactivity was precipitated by trichloroacetic acid and 75 to 80% was bound by mouse antihuman apo E. The specific activity was -7 ,uCi/,ug.
Labeled apo E was stored at 4°C in phosphate-butffered saline containing 5% FBS and used within 14 d. If kept longer there was a decrease in immunoprecipitable apo E.
Immunoglobulins were labeled by chloramine T (19) and the free 125I was removed by passage on an anion-exchange resin AGI x 8 (Bio-Rad Laboratories, Richmond, Calif.).
Radioimmunoassay. The monoclonal antibody IgG fraction (see above) was diluted in 5 mM glycine (pH 9.2), and 200-,ul aliquots were distributed in Removawells and left overnight at room temperature. The dilution of antibody was chosen on the basis of preliminary experiments and the concentration ranged from 5 to 10 munodepleted of endogenous apo E were tested for their ability to compete with 125I-apo E. Typical competition curves are shown in Fig. 2 . The lower limit of detection of purified apo E was in the range of 5 to 15 ng protein, dependent upon the individual antibody. Complete inhibition occurred with > 100-500 ng apo E, again dependent upon the antibody. At high concentration, apo AII, apo CII, and apo CIII competed with 125I-apo E, which would indicate a probable minor contamination (<1%) of these apoprotein preparations with apo E. Porcine and African green monkey plasma, even at low dilutions, competed poorly with 125I-human apo E for the monoclonal and polyclonal antihuman apo E antibody (not shown). When dilutions of human plasma or lipoprotein subfractions were tested in the RIA, the competition curves were parallel to that of purified apo E (Fig. 3) . Although delipidation, heating the sample at 45°C for 30 min, or treatment with 8 M urea caused a decrease in measurable apo E in plasma, the shape of the curve was unchanged (not shown).
The apo E concentration in the plasma of six normal, 10 type II, 10 type IV, and 2 type III subjects was determined by RIA using four monoclonal and one polyclonal mouse antihuman apo E IgG. The mean and standard deviations are given in Table I FIGURE 2 Dilutions of purified apo E (-), apo AI (x), apo AII (0), apo CII (0), apo CIII (T), and LDL previously passed over insolubilized mouse antihuman apo E (A) were tested in a RIA for their ability to compete with 1251-apo E. The five monoclonal anti-apo E antibodies or polyclonal anti-apo E IgG were used as the antibody component. The within-assay coefficient of variation was 6% when 10 replicate plasma samples were included in the assay. This value represents the mean of three experiments. The between-assay coefficient of variation was 9% when the same plasma sample was measured 15 times in duplicate over a 2-mo period.
PLASMA (nl)
The assay for apo E was validated by a series of parallel determinations of apo E levels by RIA and by densitometric scanning of apo VLDL analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Apo VLDL from four hyperlipoproteinemic patients were electrophoresed each at three different protein levels, and a linear standard curve was drawn from a series of purified apo E standards, electrophoresed, stained, and scanned in the same conditions. The correlation between the apo E levels measured by RIA and by densitometric scanning was 0.999, whereas the RIA-determined levels were 85% of those measured by scanning.
Reactivity ofmonoclonal antibodies with isomorphs of apo E. The isomorphs of apo E, isolated by preparative isoelectrofocusing, were verified by analytical isoelectrofocusing, which showed that the apo E2 fraction was slightly contaminated with apo E3, and that there was a contamination of the apo E, fraction with apo AI. In the latter case the degree of contamination was estimated by scanning the analytical gels after staining with Coomassie Blue G250 and the apo E concentration was appropriately corrected for this contamination (20) .
The individual isomorphs were tested in the RIA for their ability to compete with 125I-apo E (Fig. 4) . The antibodies recognize all of the isomorphs. With certain antibodies small differences in reactivities of individual isomorphs were seen as indicated by relative shifts of the competition curves. Although small, these differences were reproducible.
Reactivity of antibodies with chemically modified VLDL.
In an attempt to demonstrate that the different monoclonal antibodies recognize distinct antigenic determinants on apo E, the antibodies were tested for their ability to recognize apo E in chemically-modified VLDL. Lysine residues of VLDL were modified by carbamylation or by reductive methylation, and the modified lipoprotein was tested for its ability to compete in the RIA with 125I-apo-E. The (23) . Nevertheless, methods used to expose determinants of apo Al (delipidation, urea, etc.) had little effect in the present study. Furthermore, the same differences among the antibodies in absolute apo E determinations were also observed in lipoproteins isolated by ultracentrifugation, including the d > 1.21 g/ml infranate, which is relatively poor in lipid. Thus, the apparently decreased recognition by certain monoclonal antibodies of apo E incorporated in lipoproteins appears to be independent of the lipid/protein ratio and the size of the particle. Nevertheless, even relatively small amounts of lipid, as might be present in the d > 1.21 infranate, may interfere with the antibodyantigen interaction either by steric hindrance or by slightly altering apo E conformation. Alternatively, certain antibodies may be directed against determinants which had been altered during the purification of apo E on heparin-Sepharose, and their affinity may thus be higher for these altered forms than for the native determinants. On the other hand, certain antibodies against native determinants may poorly recognize altered determinants of the apo E standard, and thus overestimate apo E concentrations.
All of the antibodies recognized all of the isomorphs of apo E. Havel et al. (22) have recently shown immunological identity among the apo E isomorphs by double immunodiffusion and identical reactivity in the radioimmunoassay. With some of the antibodies, however, we did observe small relative shifts of the competition curves, which could indicate small differences in the relative affinities of the antibodies for the individual isomorphic species.
Differences among the clones in their ability to react with chemically modified proteins were observed. Modification of lysine residues of VLDL by carbamylation caused an increase in reactivity with the monoclonal antibodies 3B7, 6C5, and 6H7. In contrast, the antibody 1D7 recognized carbamylated VLDL very poorly. The 
